OCUMENSION THER.DL-00001

Research OCUMENSION THER.DL-00001 (5DG) on Bullrun: market cap EUR 438.14M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 438.14M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025CNY 804.35M-CNY 158.82M-CNY 358.65M44.9%-0.2CNY 377.46MCNY 187.54MCNY 3.68B
FY2024CNY 417.31M-CNY 268.27M-CNY 408.97M53.9%-0.39CNY 729.21MCNY 25.78MCNY 3.77B
FY2023CNY 246.37M-CNY 379.79M-CNY 539.79M58.6%-0.59CNY 842.84MCNY 137.98MCNY 2.92B
FY2022CNY 158.96M-CNY 402.64M-CNY 510.66M64.7%-0.64CNY 1.17BCNY 29.58MCNY 2.75B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-14EUR 438.14Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About OCUMENSION THER.DL-00001

Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is OCUMENSION THER.DL-00001's market cap?

OCUMENSION THER.DL-00001's market capitalization is EUR 438.14M.

What does OCUMENSION THER.DL-00001 do?

Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China. The company offers various ophthalmic drugs for the treatment of chronic non-infectious uveitis, wet age-related macular degeneration, diabetic macular edema, choroidal neovascularization, dry eye disease, glaucoma, allergic and bacterial conjunctivitis, fungus disease, and anti-inflammatory, as well as postoperative ocular inflammation, paralysis of ciliary muscle, and pupil dilation, as well as eyelid and periocular cleansing.